Meeting
2021 ASCO Annual Meeting
Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.
Presenter
Joshua Bauml, MD
Perelman School of Medicine at the University of Pennsylvania
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT02609776
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9006)
DOI
10.1200/JCO.2021.39.15_suppl.9006
Abstract #
9006
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.
Speaker: Li Zhang, MD
Videos & Slides
2024 ASCO Annual Meeting
Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study.
Speaker: Enriqueta Felip, MD, PhD
Videos & Slides
2022 ASCO Annual Meeting
Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2.
Speaker: Catherine A. Shu, MD
Videos & Slides
2021 ASCO Annual Meeting
Update analysis of NEJ009: Gefitinib alone (G) versus gefitinib plus chemotherapy (GCP) for non-small cell lung cancer with mutated EGFR.
Speaker: Eisaku Miyauchi, MD, PhD